|
Clinical News & Knowledge: Neurology
July 1, 2008
ONCOLOGY. Vol. 22 No. 8
Your Older Patient
Functional Assessment of the Older Patient With Cancer
Cathy C. Schubert, MD
Assistant Professor of Clinical Medicine Department of Internal Medicine and Geriatrics Indiana University School of Medicine Indianapolis, Indiana Cary Gross, MD Associate Professor of Medicine Department of Internal Medicine Yale University New Haven, Connecticut Arti Hurria, MD Director, Aging and Cancer Research Program Department of Medical Oncology and Therapeutics Research City of Hope Duarte, California
Polypharmacy Normal physiologic changes that accompany aging can also cause changes in the pharmacokinetics and pharmacodynamics of cancer therapy. Older adults lose muscle and gain fat as they age. Total body water decreases while percentage of body fat increases, a fact that alters the distribution of drugs in the body. In addition, renal clearance decreases, even if no elevation in blood urea nitrogen or creatinine is detected. Finally, with increasing age, blood flow to the liver is less vigorous than at younger ages, and the liver shrinks in size. These changes have an impact on hepatic metabolism. As the body ages, it can accumulate chronic diseases such as diabetes mellitus and hypertension. Many older adults who present with a new cancer diagnosis are already taking multiple medications, and cancer treatment and its side effects will likely add more. While there have been few studies about the impact of polypharmacy in cancer treatment, we do know from geriatric literature that the more medications someone is taking, the higher the risk of an adverse drug reaction (ADR).[52,53] A thorough review of a patient's medications, both prescribed and over-the-counter, can help decrease the risk of ADRs. Such an assessment allows for the identification of potential drug interactions or the need for dose adjustments to accommodate age-related changes in organ function, as well as the elimination of unnecessary medications. Having the patient bring all medication bottles to an outpatient visit provides the most accurate picture of what the person has access to and is taking. It can also corroborate compliance with a treatment regimen. Psychosocial Support In recent years, cancer care has moved from the inpatient to the outpatient setting. While beneficial on many levels for both the patient and the health-care system, this shift has thrust family and friends into caregiving roles that were previously performed by trained hospital staff. This can be particularly problematic for patients who have no social network of support, and it may be why such isolation has been associated with a greater mortality risk.[54] Asking simple questions such as: “Who would you call in an emergency?” and “Who is available to help you in times of need?” can help identify patients who are socially isolated. Depression has been shown to increase the risk of functional decline and increase health-care resource use. It is also associated with poorer survival for cancer patients. While some studies have demonstrated that a more comprehensive screen for depression is needed,[55] other studies have demonstrated that an effective screening tool for depression is to simply ask the patient if he or she feels depressed or sad.[56,57] A positive answer should be followed with further questioning for common depressive symptoms, such as anhedonia, changes in sleep patterns, crying spells, etc. The oncologist can then ask if the patient would be interested in counseling, medication, or both. These few questions can help guide the plan for further evaluation and treatment of a mood disorder. Integrating Geriatric Assessment Tools Into Oncology Practice In this article we reviewed some practical tools for assessing the functional status of older adults with cancer, as well as highlighted other domains that may affect an older adult's ability to tolerate cancer therapy. A comprehensive geriatric assessment and intervention has proven clinical benefit for optimizing health outcomes as well as improving function and quality of life in older adults.[58,59] The feasibility of including a geriatric assessment[60] as part of the baseline evaluation of older adults on clinical trials is being studied by the Cancer and Leukemia Group B Cancer in the Elderly Committee. Other approaches have been described in the literature, including a mailed geriatric assessment completed by the patient prior to an office visit, a primarily self-administered geriatric assessment, or an abbreviated geriatric assessment.[5,60-63] Studies are underway to evaluate which domains and questions from a geriatric assessment are predictive for the risk of chemotherapy toxicity. These data can guide subsequent studies of interventions to help improve tolerance to cancer therapy in older adults. Ultimately, the integration of knowledge learned in the fields of both geriatrics and oncology will optimize cancer care for older adults. This article is reviewed here: Translation Requires Evidence: Does Cancer-Specific CGA Lead to Better Care and Outcomes?
This article reviewed
Address all correspondence to:
Arti Hurria, md City of Hope 1500 E. Duarte Rd Duarte, CA 91010 e-mail: ahurria@coh.org
References
1. Ries LAG, Harkins D, Krapcho M, et al: SEER Cancer Statistics Review, 1975-2003. National Cancer Institute; Bethesda, Md; 2006. 2. Reuben DB, Rubenstein LV, Hirsch SH, et al: Value of functional status as a predictor of mortality: Results of a prospective study. Am J Med 93:663-669, 1992. 3. Balducci L, Beghe C: The application of the principles of geriatrics to the management of the older person with cancer. Crit Rev Oncol Hematol 35:147-154, 2000. 4. Repetto L, Fratino L, Audisio RA, et al: Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: An Italian Group for Geriatric Oncology Study. J Clin Oncol 20:494-502, 2002. 5. Extermann M, Hurria A: Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 25:1824-1831, 2007. 6. Freyer G, Geay JF, Touzet S, et al: Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: A GINECO study. Ann Oncol 16:1795-1800, 2005. 7. Ponzetto M, Maero B, Maina P, et al: Risk factors for early and late mortality in hospitalized older patients: The continuing importance of functional status. J Gerontol A Biol Sci Med Sci 58:1049-1054, 2003. 8. Mor V, Wilcox V, Rakowski W, et al: Functional transitions among the elderly: Patterns, predictors, and related hospital use. Am J Public Health 84:1274-1280, 1994. 9. Maione P, Perrone F, Gallo C, et al: Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: A prognostic analysis of the multicenter Italian lung cancer in the elderly study. J Clin Oncol 23:6865-6872, 2005. 10. Flood KL, Carroll MB, Le CV, et al: Geriatric syndromes in elderly patients admitted to an oncology-acute care for elders unit. J Clin Oncol 24:2298-2303, 2006. 11. Cohen HJ, Saltz CC, Samsa G, et al: Predictors of two-year post-hospitalization mortality among elderly veterans in a study evaluating a geriatric consultation team. J Am Geriatr Soc 40:1231-1235, 1992. 12. Brach JS, VanSwearingen JM, Newman AB, et al: Identifying early decline of physical function in community-dwelling older women: performance-based and self-report measures. Phys Ther 82:320-328, 2002. 13. Guralnik JM, Simonsick EM, Ferrucci L, et al: A short physical performance battery assessing lower extremity function: Association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol 49:M85-M94, 1994. 14. Guralnik JM, Ferrucci L, Simonsick EM, et al: Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability. N Engl J Med 332:556-561, 1995. 15. Podsiadlo D, Richardson S: The timed “Up & Go”: A test of basic functional mobility for frail elderly persons. J Am Geriatr Soc 39:142-148, 1991. 16. Studenski S, Perera S, Wallace D, et al: Physical performance measures in the clinical setting. J Am Geriatr Soc 51:314-322, 2003. 17. Perera S, Studenski S, Chandler JM, et al: Magnitude and patterns of decline in health and function in 1 year affect subsequent 5-year survival. J Gerontol A Biol Sci Med Sci 60:894-900, 2005. 18. Malmstrom TK, Wolinsky FD, Andresen EM, et al: Cognitive ability and physical performance in middle-aged African Americans. J Am Geriatr Soc 53:997-1001, 2005. 19. Tabbarah M, Crimmins EM, Seeman TE: The relationship between cognitive and physical performance: MacArthur Studies of Successful Aging. J Gerontol A Biol Sci Med Sci 57:M228-M235, 2002. 20. Fitzpatrick AL, Buchanan CK, Nahin RL, et al: Associations of gait speed and other measures of physical function with cognition in a healthy cohort of elderly persons. J Gerontol A Biol Sci Med Sci 62:1244-1251, 2007. 21. Coppin AK, Shumway-Cook A, Saczynski JS, et al: Association of executive function and performance of dual-task physical tests among older adults: Analyses from the InChianti study. Age Ageing 35:619-624, 2006. 22. Carlson MC, Fried LP, Xue QL, et al: Association between executive attention and physical functional performance in community-dwelling older women. J Gerontol B Psychol Sci Soc Sci 54:S262-S270, 1999. 23. Atkinson HH, Rosano C, Simonsick EM, et al: Cognitive function, gait speed decline, and comorbidities: The health, aging and body composition study. J Gerontol A Biol Sci Med Sci 62:844-850, 2007. 24. Larson EB, Shadlen MF, Wang L, et al: Survival after initial diagnosis of Alzheimer disease. Ann Intern Med 140:501-509, 2004. 25. Hurria A, Goldfarb S, Rosen C, et al: Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient's perspective. Breast Cancer Res Treat 98:343-348, 2006. 26. Hurria A, Rosen C, Hudis C, et al: Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: A pilot prospective longitudinal study. J Am Geriatr Soc 54:925-931, 2006. 27. Sirigirireddy V, Boustani M, Hannah N, et al: Post-chemotherapy acute and chronic cognitive deficits. American Geriatrics Society 2007 Annual Scientific Meeting (abstract C130). J Am Geriatr Soc 55(suppl 1):S156, 2007. 28. Folstein MF, Folstein SE, McHugh PR:“Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189-198, 1975. 29. Callahan CM, Unverzagt FW, Hui SL, et al: Six-item screener to identify cognitive impairment among potential subjects for clinical research. Med Care 40:771-781, 2002. 30. Sunderland T, Hill JL, Mellow AM, et al: Clock drawing in Alzheimer's disease. A novel measure of dementia severity. J Am Geriatr Soc 37:725-759, 1989. 31. Katzman R, Brown T, Fuld P, et al: Validation of a short Orientation-Memory-Concentration Test of cognitive impairment. Am J Psychiatry 140:734-739, 1983. 32. Extermann M: Measurement and impact of comorbidity in older cancer patients. Crit Rev Oncol Hematol 35:181-200, 2000. 33. Extermann M, Overcash J, Lyman GH, et al: Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 16:1582-1587, 1998. 34. Balducci L, Extermann M: Management of cancer in the older person: A practical approach. Oncologist 5:224-237, 2000. 35. Extermann M: Studies of comprehensive geriatric assessment in patients with cancer. Cancer Control 10:463-468, 2003. 36. Linjakumpu T, Hartikainen S, Klaukka T, et al: Use of medications and polypharmacy are increasing among the elderly. J Clin Epidemiol 55:809-817, 2002. 37. Corcoran M: Polypharmacy in the older patient with cancer. Cancer Control 4:419-428, 1997. 38. Gross CP, McAvay GJ, Krumholz HM, et al: The effect of age and chronic illness on life expectancy after a diagnosis of colorectal cancer: Implications for screening. Ann Intern Med 145:646-653, 2006. 39. Charlson M, Szatrowski TP, Peterson J, et al: Validation of a combined comorbidity index. J Clin Epidemiol 47:1245-1251, 1994. 40. Charlson ME, Pompei P, Ales KL, et al: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373-383, 1987. 41. Piccirillo JF, Tierney RM, Costas I, et al: Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 291:2441-2447, 2004. 42. Lee SJ, Lindquist K, Segal MR, et al: Development and validation of a prognostic index for 4-year mortality in older adults. JAMA 295:801-808, 2006. 43. Krumholz H, Chen J, Wang Y, et al: Comparing AMI mortality among hospitals in patients 65 years of age and older. Circulation 99:2986-2992, 1999. 44. Fleming ST, Pearce KA, McDavid K, et al: The development and validation of a comorbidity index for prostate cancer among Black men. J Clin Epidemiol 56:1064-1075, 2003. 45. Byles JE, D'Este C, Parkinson L, et al: Single index of multimorbidity did not predict multiple outcomes. J Clin Epidemiol 58:997-1005, 2005. 46. Lemmens V, Janssen-Heijnen M, Houterman S, et al: Which comorbid conditions predict complications after surgery for colorectal cancer? World J Surg 31:192-99, 2007. 47. Cho CY, Alessi CA, Cho M, et al: The association between chronic illness and functional change among participants in a comprehensive geriatric assessment program. J Am Geriatr Soc 46:677-682, 1998. 48. Guigoz Y: The Mini Nutritional Assessment (MNA) review of the literature—what does it tell us? J Nutr Health Aging 10:466-487 (incl discussion), 2006. 49. Dewys WD, Begg C, Lavin PT, et al: Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 69:491-497, 1980. 50. Newman AB, Yanez D, Harris T, et al: Weight change in old age and its association with mortality. J Am Geriatr Soc 49:1309-1318, 2001. 51. Guigoz Y, Vellas B, Garry PJ: Assessing the nutritional status of the elderly: The Mini Nutritional Assessment as part of the geriatric evaluation. Nutr Rev 54:S59-S65, 1996. 52. Field TS, Gurwitz JH, Avorn J, et al: Risk factors for adverse drug events among nursing home residents. Arch Intern Med 161:1629-1634, 2001. 53. Field TS, Gurwitz JH, Harrold LR, et al: Risk factors for adverse drug events among older adults in the ambulatory setting. J Am Geriatr Soc 52:1349-1354, 2004. 54. Seeman TE, Berkman LF, Kohout F, et al: Intercommunity variations in the association between social ties and mortality in the elderly. A comparative analysis of three communities. Ann Epidemiol 3:325-335, 1993. 55. Osborn DP, Fletcher AE, Smeeth L, et al: Performance of a single screening question for depression in a representative sample of 13 670 people aged 75 and over in the UK: Results from the MRC trial of assessment and management of older people in the community. Fam Pract 20:682-684, 2003. 56. Mahoney J, Drinka TJ, Abler R, et al: Screening for depression: Single question versus GDS. J Am Geriatr Soc 42:1006-1008, 1994. 57. Chochinov HM, Wilson KG, Enns M, et al: “Are you depressed?” Screening for depression in the terminally ill. Am J Psychiatry 154:674-676, 1997. 58. Stuck AE, Siu AL, Wieland GD, et al: Comprehensive geriatric assessment: A meta-analysis of controlled trials. Lancet 342:1032-1036, 1993. 59. Cohen HJ, Feussner JR, Weinberger M, et al: A controlled trial of inpatient and outpatient geriatric evaluation and management. N Engl J Med 346:905-912, 2002. 60. Hurria A, Gupta S, Zauderer M, et al: Developing a cancer-specific geriatric assessment: A feasibility study. Cancer 104:1998-2005, 2005. 61. Ingram SS, Seo PH, Martell RE, et al: Comprehensive assessment of the elderly cancer patient: The feasibility of self-report methodology. J Clin Oncol 20:770-775, 2002. 62. Hurria A, Lichtman SM, Gardes J, et al: Identifying vulnerable older adults with cancer: Integrating geriatric assessment into oncology practice. J Am Geriatr Soc 55:1604-1608, 2007. 63. Overcash J, Extermann M, Parr J, et al: Validity and reliability of the FACT-G scale for use in the older person with cancer. Am J Clin Oncol 24:591-596, 2001. 64. Carey EC, Walter LC, Lindquist K, et al: Development and validation of a functional morbidity index to predict mortality in community-dwelling elders. J Gen Intern Med 19:1027-1033, 2004. 65. Newman AB, Simonsick EM, Naydeck BL, et al: Association of long-distance corridor walk performance with mortality, cardiovascular disease, mobility limitation, and disability. JAMA 295:2018-2026, 2006. |
|